CALGB 10002 - Phase II Study of Rituximab and Short Duration, High Intensity Chemotherapy with G-CSF Support in Previously Untreated Patients with Burkitt Lymphoma/Leukemia
CALGB 50303 - Phase III Randomized Study of R-Chop V. Dose-Adjusted Epoch-R (DA-EPOCH-R) with Molecular Profiling in Untreated De Novo Diffuse Large B-Cell Lymphomas
GCC 0851 - Phase II Trial of Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Follicular Non-Hodgkin's Lymphoma Beyond First Complete Response. BMT/CTN 0701
GCC 0854 - A Multicenter, Phase II Trial of Non-myeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow for Patients with Hematologic Malignancies. BMT/CTN 0603
GCC 0908 - An Open-Label, Phase 1 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Patients with Advanced Hematological Malignancies
GCC 0922 - Phase II Trial of Bortezomib and Vorinostat in Mantle Cell and Diffuse Large B-cell Lymphomas. NCI Protocol 8064
Email this Page
Print this Page
